Medical Condition News

RSS

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

Chelsea Therapeutics International, Ltd. announced that data from its pivotal studies of Northera™ (droxidopa) in symptomatic neurogenic orthostatic hypotension was presented during a poster session and featured in a symposium highlighting the role of norepinephrine (NE) deficiency in Parkinson's disease at the 14th International Congress on Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

17 Jun 2010

MicroPulse protocol as effective as ETDRS in treatment of DME: Study

IRIDEX Corporation announced the recent publication of a clinical study comparing results obtained in the treatment of diabetic macular edema (DME) using an IRIDEX laser and MicroPulse™ treatment protocol to those obtained using the recognized standard of care Early Treatment of Diabetic Retinopathy Study (ETDRS) laser protocol.

17 Jun 2010

LWW sponsors symposium on wound care

The 25th Anniversary Clinical Symposium on Advances in Skin & Wound Care: The Conference for Prevention and Healing will be held September 30-October 3, 2010, at the Gaylord Palms Hotel and Convention Center in Kissimee, FL. The symposium is sponsored by Lippincott Williams & Wilkins (LWW), part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

17 Jun 2010

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Within the first week after giving birth, up to 70 percent of all women experience symptoms of the baby blues. While most women recover quickly, up to 13 percent of all new mothers suffer from symptoms of a clinical-level postpartum depression. Postpartum depression is defined as a major depressive episode starting within 4 weeks after delivery and is a significant public health problem. Postpartum blues represents a major risk factor for developing postpartum depression and severe postpartum blues symptoms can be viewed as a prodromal stage for postpartum depression.

17 Jun 2010

Traumatic sexual incidents may cause serious mental health problems: Research

Traumatic sexual incidents may cause serious mental health problems in the years after the events, research at the University of Ulster has shown. Using a unique investigative method, researchers at the University's Psychology Research Institute examined the mental health of women who had visited rape crisis centres - and it showed that sexual trauma plays a role in the development of psychotic disorders such as schizophrenia.

17 Jun 2010

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.

17 Jun 2010

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

Neurocrine Biosciences, Inc. announced today that they have established a worldwide collaboration with Boehringer Ingelheim to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications. The companies will work jointly to identify and advance candidates into pre-clinical development. Boehringer Ingelheim is responsible for the global development and commercialization of potential GPR119 agonist products.

17 Jun 2010

No evidence on health benefits of oxygen inhalation during heart attack: Researchers

There is no evidence that the common practice of giving patients oxygen to inhale during a heart attack is beneficial, according to a new Cochrane Systematic Review. Until further research is carried out, the researchers say the possibility that giving oxygen may actually increase a patient's risk of dying cannot be ruled out.

17 Jun 2010

Proportion of substance abuse treatment admissions involving older Americans doubles: SAMHSA

A new study reveals that between 1992 and 2008 the proportion of substance abuse treatment admissions involving older Americans (aged 50 and older) nearly doubled -- from 6.6 percent of all admissions in 1992 to 12.2 percent in 2008. The study, sponsored by the Substance Abuse and Mental Health Services Administration, also shows a sharp rise during this period in the proportion of older Americans admissions related to illicit drug abuse -- even though alcohol abuse is still the leading cause for admissions involving this age group.

17 Jun 2010

New book gives hope to women and families who are in difficult stages of anorexia treatment

Women and families struggling with an eating disorder or another addiction should never lose sight of the need to sustain the spirit, according to a new book by Jena Morrow, an author in recovery after more than 20 years with anorexia nervosa. Morrow, a behavioral health specialist at Timberline Knolls Residential Treatment Center, details a battle with anorexia that begins in early childhood in Hollow: An Unpolished Tale, recently released by Moody Publishers.

17 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).

17 Jun 2010

Implications for reducing clotting in kidney disease dialysis and sepsis

The interaction of the drug compstatin with two ancient, co-evolved human systems points to new ways for reducing clotting during dialysis for end-stage kidney disease and multiple organ failure due to sepsis, a dangerous whole-body inflammatory response to infection.

17 Jun 2010

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-76, one of two pivotal Phase 3 trials of BENLYSTA® (belimumab) in seropositive patients with systemic lupus erythematosus (SLE). The results will be presented today in Rome at the 2010 Congress of the European League Against Rheumatism (EULAR).

17 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Four out of ten high-risk patients prescribed nonsteroidal anti-inflammatory drugs also received appropriate measures to prevent upper-gastrointestinal problems, but the remainder did not receive adequate protection, according to a study in the June issue of Alimentary Pharmacology and Therapeutics.

17 Jun 2010

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

In diverse neurodegenerative diseases ranging from Parkinson's to Alzheimer's, researchers have long noted accumulations of a little-understood neuronal protein called α-synuclein. Pathological and genetic evidence strongly suggested that excessive α-synuclein played a role in the evolution of these diseases, but it was unclear how too much α-synuclein culminated in synaptic damage and neurodegeneration.

17 Jun 2010

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Keppra® Injection, levetiracetam injection.

17 Jun 2010

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

A research team from McGill University (Canada) report a beneficial effect on cardiac function in mouse models when implanted monocytes - a type of white blood cell that is part of the immune system - helped preserve cardiac function following a heart attack (myocardial infarction).

17 Jun 2010

Researchers identify peptide that triggers diabetes

Researchers at National Jewish Health and the University of Colorado Anschutz Medical Campus have identified the precise protein fragment, or peptide, that can trigger diabetes in mice. The finding, published in the June 15, 2010, issue of the Proceedings of the National Academy of Sciences, supports an emerging theory about the origins of autoimmunity, and may lead to new diagnostic and therapeutic strategies in humans.

17 Jun 2010

Medical Condition News

Chelsea presents Northera study data at International Congress on Parkinson's Disease and Movement Disorders

MicroPulse protocol as effective as ETDRS in treatment of DME: Study

LWW sponsors symposium on wound care

Study reveals increase of enzyme MAO-A in female brain during immediate postpartum period

Traumatic sexual incidents may cause serious mental health problems: Research

Positive results from Phase I clinical trial of GLYX-13 presented at NCDEU meeting

Neurocrine Biosciences, Boehringer Ingelheim collaborate to develop GPR119 agonists for Type II diabetes

No evidence on health benefits of oxygen inhalation during heart attack: Researchers

Proportion of substance abuse treatment admissions involving older Americans doubles: SAMHSA

New book gives hope to women and families who are in difficult stages of anorexia treatment

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

Positive Phase I results from ChemoCentryx CCX354 study for RA presented at EULAR

Implications for reducing clotting in kidney disease dialysis and sepsis

HGS, GSK announce full presentation of BLISS-76 Phase 3 BENLYSTA trial results for SLE at EULAR 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Patients prescribed NSAIDs also receive appropriate measures to prevent UGI problems: Study

Excess neuronal protein plays role in the evolution of neurodegenerative diseases: Research

USFDA approves Sun Pharma's generic Keppra Injection ANDA

Researchers assess effect of MDs on cardiac and endothelial cell proliferation, survival

Researchers identify peptide that triggers diabetes

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News